Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
1.45 ^USD	-1.31%		+16.00%	-22.04%

05-14	Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-22	Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	MT

Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 30, 2023 at 10:00 pm

Adial Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 12.73 million compared to USD 19.42 million a year ago. Basic loss per share from continuing operations was USD 12.75 compared to USD 26 a year ago.

Latest news about Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	04-22	MT
Top Premarket Decliners	04-12	MT
Top Midday Gainers	04-10	MT
Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder	04-10	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding	03-13	CI
Adial Pharmaceuticals, Inc. announced that it expects to receive $0.2875 million in funding	03-05	CI
Top Premarket Decliners	03-04	MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	03-01	MT
US Futures Remain Flat as Investors Await Raft of Economic Data	03-01	MT
Top Midday Gainers	02-28	MT
Adial Pharmaceuticals Secures US Patent Allowance for AD04, Genetic Diagnostic Combination	02-13	MT
Adial Pharmaceuticals Receives New Patent Notice of Allowance from the United States Patent and Trademark Office	02-13	CI
Adial Pharmaceuticals Appoints Tony Goodmans as Chief Operating Officer	01-18	MT
Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer	01-18	CI
Top Premarket Gainers	11-30	MT
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding	23/10/23	CI
Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding	19/10/23	CI
Adial Pharmaceuticals Awarded Patent Combining Use of Genetic Diagnostic With AD04 to Treat Alcohol, Drug Dependence	19/10/23	MT
Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence	19/10/23	CI
Adial Pharmaceuticals, Inc. Announces Board Changes	21/09/23	CI
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
Adial Pharma to Conduct Two More AD04 Phase 3 Trials After Regulatory Feedback	11/07/23	DJ

Chart Adial Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Companyâs lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Companyâs ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Companyâs companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Companyâs wholly owned subsidiary is Purnovate, Inc.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - MicroCap Rodeo Spring into Summer Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.45 USD

Average target price

7.5 USD

Spread / Average Target

+417.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADIAL PHARMACEUTICALS, INC.	-22.04%	5.88M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.15%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research